Generated by AI
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer. Its current pipeline centers on antibody radiation conjugates and actinium-225-based programs designed to deliver radiation directly to tumor cells while limiting exposure to healthy tissue. The company’s lead product candidate, ATNM-400, is being developed as a multi-indication therapy for solid tumors including prostate cancer, non-small cell lung cancer, and breast cancer. Actinium is also advancing Actimab-A for hematologic malignancies such as acute myeloid leukemia, along with Iomab-ACT for conditioning before gene and cell therapies. Through these programs, Actinium Pharmaceuticals, Inc. plays a specialized role in precision oncology, addressing both solid tumor and blood cancer settings with radiopharmaceutical approaches.
Website100 Park Avenue
New York, NY, 10017
United States
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
Summary of Nov 1's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about ATNM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.